Αποτελέσματα Αναζήτησης
15 Οκτ 2010 · In the placebo-controlled phase III SATURN study, maintenance erlotinib after first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) and overall survival (OS) in the overall study population of patients with advanced non-small-cell lung cancer (NSCLC).
Forgot Password? Official Login page for Canvas student login, School Search Canvas, Canvas Network, Canvas Community, and Canvas Free For Teacher accounts.
The Sequential Tarceva in Unresectable NSCLC (SATURN) trial was designed to investigate the effectiveness of maintenance erlotinib treatment until the time of progression, with the goal of prolonging overall survival and delaying disease progression .
Erlotinib (Tarceva) is a small-molecule, orally dosed, anti-cancer drug that inhibits the epidermal growth factor receptor. Randomized, controlled clinical studies have demonstrated that erlotinib significantly improved survival in patients with ...
The Sequential Tarceva in Unresectable NSCLC (SATURN) study investigated the use of maintenance erlotinib following the completion of first-line chemotherapy.
Now you can take your Saturn Calendar to college when you graduate from high school. Saturn is the calendar built for high school. It's the only calendar capable of supporting the complexities of the high school day, is built around your friends, and is truly realtime.
2 Αυγ 2009 · August 1, 2009 (San Francisco, California) — New results from the phase 3 SATURN trial show that erlotinib (Tarceva) maintenance therapy significantly improves overall survival in...
